Daré Bioscience, Inc. (DARE) Earnings History
Annual and quarterly earnings data from 2011 to 2024
Loading earnings history...
DARE EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
DARE Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | -146110.2% | -239692.2% | -41430.9% |
| 2023 | -670.6% | -1101.9% | -1074.2% |
| 2022 | -201.4% | -313.9% | -309.5% |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export DARE earnings history in CSV or JSON format
Free sign-in required to download data
Daré Bioscience, Inc. (DARE) Earnings Overview
As of May 8, 2026, Daré Bioscience, Inc. (DARE) reported trailing twelve-month net income of -$17M, reflecting +88.4% year-over-year growth. The company earned $-1.37 per diluted share over the past four quarters, with a net profit margin of -41430.9%.
Looking at the long-term picture, DARE's historical earnings data spans multiple years. The company achieved its highest annual net income of -$4M in fiscal 2024, representing a new all-time high.
Daré Bioscience, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including TPVG (-$12M net income, 50.6% margin), EVAX (-$8M net income, -102.4% margin), CODA ($4M net income, 15.5% margin), DARE has room to improve margins relative to the peer group. Compare DARE vs TPVG →
DARE Earnings vs Peers
Earnings metrics vs comparable public companies
DARE Historical Earnings Data (2011–2024)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$4M | +86.6% | -$23M | $-0.48 | -41430.9% | -239692.2% |
| 2023 | -$30M | +2.5% | -$31M | $-4.15 | -1074.2% | -1101.9% |
| 2022 | -$31M | +20.0% | -$31M | $-4.39 | -309.5% | -313.9% |
| 2021 | -$39M | -41.2% | -$39M | $-7.52 | - | - |
| 2020 | -$27M | -92.1% | -$27M | $-10.93 | - | - |
| 2019 | -$14M | +14.8% | -$14M | $-10.99 | - | - |
| 2018 | -$17M | -45.5% | -$17M | $-30.16 | - | - |
| 2017 | -$12M | +70.7% | -$11M | $-3.56 | - | - |
| 2016 | -$39M | +0.7% | -$37M | $-30.02 | -5131.2% | -4850.4% |
| 2015 | -$40M | -69.6% | -$37M | $-15.57 | - | - |
See DARE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DARE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DARE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonDARE — Frequently Asked Questions
Quick answers to the most common questions about buying DARE stock.
Is DARE growing earnings?
DARE EPS is $-1.37, with earnings growth accelerating to +88.4%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-17M.
What are DARE's profit margins?
Daré Bioscience, Inc. net margin is -41430.9%, with operating margin at -239692.2%. Below-average margins reflect competitive or cost pressures.
How consistent are DARE's earnings?
DARE earnings data spans 2011-2024. The accelerating earnings trend is +88.4% YoY. Historical data enables comparison across business cycles.